Epitope-mapping of the glycoprotein from Crimean-Congo hemorrhagic fever virus using a microarray approach

PLoS Neglected Tropical Diseases

Volumn 12, Issue 7, 2018, Pages

  Fritzen, Amanda ^a   Risinger, Christian ^a   Korukluoglu, Gulay ^b   Christova, Iva ^c   Corli Hitzeroth, Arina ^d   Viljoen, Natalie ^d   Burt, Felicity Jane ^d,e   Mirazimi, Ali ^f,g,h   Blixt, Ola ^a,g  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Refik Saydam National Public Health Agency   (Turkey)

^c NATIONAL CENTER OF INFECTIOUS AND PARASITIC DISEASES   (Bulgaria)

^d UNIVERSITY OF THE FREE STATE   (South Africa)

^e NHLS Universitas   (South Africa)

^f SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^g KAROLINSKA INSTITUTE   (Sweden)

^h NATIONAL VETERINARY INSTITUTE   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; VIRAL PROTEIN; VIRUS ANTIBODY;

ADULT; AMINO ACID ANALYSIS; AMINO ACID SEQUENCE; ARTICLE; CASE CONTROL STUDY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; CRIMEAN CONGO HEMORRHAGIC FEVER; CRIMEAN-CONGO HEMORRHAGIC FEVER VIRUS; DISEASE TRANSMISSION; EPITOPE MAPPING; FEMALE; GENETIC VARIABILITY; HUMAN; IMMUNE RESPONSE; IMMUNOREACTIVITY; MALE; MICROARRAY ANALYSIS; MORTALITY RATE; OBSERVATIONAL STUDY; PEPTIDE ASSAY; PROTEIN ANALYSIS; SENSITIVITY AND SPECIFICITY; SEROLOGY; SOLID PHASE PEPTIDE SYNTHESIS; SOUTH AFRICA; TURKEY (REPUBLIC); VIRUS TRANSMISSION; CHEMISTRY; GENETICS; IMMUNOLOGY; PEPTIDE LIBRARY; TURKEY (BIRD); VIROLOGY;

ANTIBODIES, VIRAL; EPITOPE MAPPING; GLYCOPROTEINS; HEMORRHAGIC FEVER VIRUS, CRIMEAN-CONGO; HEMORRHAGIC FEVER, CRIMEAN; HUMANS; MICROARRAY ANALYSIS; PEPTIDE LIBRARY; SOUTH AFRICA; TURKEY; VIRAL PROTEINS;

EID: 85050769128     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0006598     Document Type: Article

References (24)

1. Whitehouse CA, Crimean-Congo hemorrhagic fever. Antiviral Research. 2004. pp. 145–160. doi: 10.1016/j.antiviral.2004.08.001 pmid: 15550268
2. Bente D a., Forrester NL, Watts DM, McAuley AJ, Whitehouse C a., Bray M, Crimean-Congo hemorrhagic fever: History, epidemiology, pathogenesis, clinical syndrome and genetic diversity. Antiviral Res. 2013;100: 159–189. doi: 10.1016/j.antiviral.2013.07.006 pmid: 23906741
3. Negredo A, de la Calle-Prieto F, Palencia-Herrejón E, Mora-Rillo M, Astray-Mochales J, Sánchez-Seco MP, et al. Autochthonous Crimean–Congo Hemorrhagic Fever in Spain. N Engl J Med. 2017;377: 154–161. doi: 10.1056/NEJMoa1615162 pmid: 28700843
4. Papa A, Dalla V, Papadimitriou E, Kartalis GN, Antoniadis A, Emergence of Crimean-Congo haemorrhagic fever in Greece. Clin Microbiol Infect. 2010;16: 843–847. doi: 10.1111/j.1469-0691.2009.02996.x pmid: 19845692
5. Mishra AC, Mehta M, Mourya DT, Gandhi S, Crimean-Congo haemorrhagic fever in India. The Lancet. 2011. p. 372. doi: 10.1016/S0140-6736(11)60680-6
6. Maltezou HC, Andonova L, Andraghetti R, Bouloy M, Ergonul O, Jongejan F, et al. Crimean-congo hemorrhagic fever in Europe: Current situation calls for preparedness. Eurosurveillance. 2010;15: 48–51.
7. Estrada-Peña A, Palomar AM, Santibáñez P, Sánchez N, Habela MA, Portillo A, et al. Crimean-congo hemorrhagic fever virus in ticks, Southwestern Europe, 2010. Emerging Infectious Diseases. 2012. pp. 179–180. doi: 10.3201/eid1801.111040 pmid: 22261502
8. Vanhomwegen J, Alves MJ, Zupanc TA, Bino S, Chinikar S, Karlberg H, et al. Diagnostic assays for Crimean-Congo hemorrhagic fever. Emerg Infect Dis. 2012;18: 1958–1965. doi: 10.3201/eid1812.120710 pmid: 23171700
9. Burt FJ, Leman PA, Abbott JC, Swanepoel R, Serodiagnosis of Crimean-Congo haemorrhagic fever. Epidemiol Infect. 1994;113: 551–562. doi: 10.1017/S0950268800068576 pmid: 7995364
10. Weidmann M, Avsic-Zupanc T, Bino S, Bouloy M, Burt F, Chinikar S, et al. Biosafety standards for working with crimean-congo hemorrhagic fever virus. J Gen Virol. 2016;97: 2799–2808. doi: 10.1099/jgv.0.000610 pmid: 27667586
11. Sanchez AJ, Vincent MJ, Nichol ST, Characterization of the glycoproteins of Crimean-Congo hemorrhagic fever virus. J Virol. 2002;76: 7263–75. doi: 10.1128/JVI.76.14.7263-7275.2002 pmid: 12072526
12. Li W, Joshi M, Singhania S, Ramsey K, Murthy A, Peptide Vaccine: Progress and Challenges. Vaccines. 2014;2: 515–536. doi: 10.3390/vaccines2030515 pmid: 26344743
13. Goedhals D, Paweska JT, Burt FJ, Identification of human linear B-cell epitope sites on the envelope glycoproteins of Crimean-Congo haemorrhagic fever virus. Epidemiol Infect. 2014; 1–6. doi: 10.1017/S0950268814002271 pmid: 25185583
14. Blixt O, Clo E, Nudelman AS, Sørensen KK, Clausen T, Wandall HH, et al. A High-Throughput O-Glycopeptide Discovery Platform for Seromic Profiling research articles. 2010; 5250–5261.
15. Clo E, Kracun SK, Nudelman AS, Jensen KJ, Liljeqvist J-A, Olofsson S, et al. Characterization of the Viral O-Glycopeptidome: a Novel Tool of Relevance for Vaccine Design and Serodiagnosis. J Virol. 2012;86: 6268–6278. doi: 10.1128/JVI.00392-12 pmid: 22491453
16. D’Arrigo I, Cló E, Bergström T, Olofsson S, Blixt O, Diverse IgG serum response to novel glycopeptide epitopes detected within immunodominant stretches of Epstein-Barr virus glycoprotein 350/220: Diagnostic potential of O-glycopeptide microarrays. Glycoconj J. 2013;30: 633–640. doi: 10.1007/s10719-012-9465-3 pmid: 23292036
17. Blixt O, Cló E, Nudelman AS, Sørensen KK, Clausen T, Wandall HH, et al. A high-throughput O-glycopeptide discovery platform for seromic profiling. J Proteome Res. 2010;9: 5250–5261. doi: 10.1021/pr1005229 pmid: 20726594
18. Blixt O, Cló E, Synthesis of O-glycopeptides and construction of glycopeptide microarrays. Methods Mol Biol. 2013;1047: 201–214. doi: 10.1007/978-1-62703-544-6_14 pmid: 23943488
19. Risinger C, Sørensen KK, Jensen KJ, Olofsson S, Bergström T, Blixt O, Linear Multiepitope (Glyco)peptides for Type-Specific Serology of Herpes Simplex Virus (HSV) Infections. ACS Infect Dis. 2017;3: 360–367. doi: 10.1021/acsinfecdis.7b00001 pmid: 28238255
20. Mousavi-Jazi M, Karlberg H, Papa A, Christova I, Mirazimi A, Healthy individuals’ immune response to the Bulgarian Crimean-Congo hemorrhagic fever virus vaccine. Vaccine. 2012;30: 6225–9. doi: 10.1016/j.vaccine.2012.08.003 pmid: 22902680
21. Martinez O, Tabtral L, Mulherkar N, Chandran K, Basler CF, Impact of Ebola mucin-like domain on antiglycoprotein antibody responses induced by Ebola virus-like particles. J Infect Dis2011; 204: S825–32. doi: 10.1093/infdis/jir295 pmid: 21987758
22. Goedhals D, Paweska JT, Burt FJ, Long-lived CD8+ T cell responses following Crimean- Congo haemorrhagic fever virus infection. PLoS Negl Trop Dis. 2017Dec;11(12):e0006149. doi: 10.1371/journal.pntd.0006149 pmid: 29261651
23. Dowall SD, Graham VA, Rayner E, Hunter L, Watson R, Taylor I, Rule A, Carroll MW, Hewson R, Protective effects of a modified vaccinia Ankara-based vaccine candidate against Crimean-Congo haemorrhagic fever virus requires both cellular and humoral immune responses. PLOS One2016; 11:e0156637. doi: 10.1371/journal.pone.0156637 pmid: 27272940
24. Goedhals D, Bester PA, Paweska JT, Swanepoel R, Burt FJ,. (2015) Comparative analysis of the L, M and S RNA segments of Crimean-Congo haemorrhagic fever virus isolates from southern Africa. J Med Virol87(5):717–724. doi: 10.1002/jmv.24079 pmid: 25693737